Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pozen, under its agreement with AstraZeneca for Vimovo, is set to receive a $25m milestone payment within 20 days.
Subscribe to our email newsletter
Pozen is expected to receive the milestone as a result of the grant of marketing and pricing approval for Vimovo (naproxen/ esomeprazole magnesium) 500/20mg modified-release tablets in the UK.
Vimovo, co-developed by Pozen and AstraZeneca, is a fixed-dose combination of delayed-release enteric-coated naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID), and immediate release esomeprazole, a proton pump inhibitor (PPI).
Vimovo is indicated for the symptomatic treatment of osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS) in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.
Pozen chairman, president and CEO John Plachetka said that they were looking forward to using the milestone to continue to fund and advance the development of their PA portfolio.
Pozen claimed that the products in the PA portfolio are intended to significantly reduce gastrointestinal (GI) ulcers and other GI complications compared to taking aspirin alone.